



Systemic sclerosis (SSc) is a DEBILITATING, CHRONIC AUTOIMMUNE DISEASE that causes the body's immune system to **ATTACK ITS OWN TISSUE**¹

The underlying **CAUSE IS UNKNOWN** and it is potentially fatal^{1,2}

There are two main types:^{1,3}



VS



LIMITED CUTANEOUS
was previously known as CREST syndrome – milder and **AFFECTS THE SKIN**

DIFFUSE CUTANEOUS
more widespread on the **SKIN AND CAN AFFECT INTERNAL ORGANS**

SSc is a RARE DISEASE and has a highly detrimental impact on the **2.5 million people** it affects around the world⁴

It's three-to-four times more likely to affect women than men.⁵ **ANY AGE GROUP** can be affected, but mainly occurs in **ADULTS AGED 30-50**¹



2.5 MILLION

Prevalence varies widely across the world, but the **REASONS ARE UNKNOWN**⁶

SSc can affect INTERNAL ORGANS as well as the SKIN¹

SSc causes **THICKENING OF THE SKIN** and can **DISFIGURE** the most publicly visible body parts such as the **FACE AND HANDS**¹



It can cause potentially **FATAL DAMAGE** to internal organs such as the **HEART and BLOOD VESSELS, LUNGS, STOMACH and KIDNEYS**^{1,2}



SSc can IMPACT LIFE EXPECTANCY and QUALITY OF LIFE^{2,7-11}



AVERAGE SURVIVAL for SSc is only approx. **11 YEARS** from diagnosis⁷



It has the **HIGHEST DEATH RATE** of any rheumatic condition²



Symptoms can lead to **DISSATISFACTION WITH BODY IMAGE**, affect social relationships and significantly **DECREASE QUALITY OF LIFE**^{8,9}



Up to **65%** of people with SSc report symptoms of **ANXIETY AND DEPRESSION**^{10,11}

There are CURRENTLY NO DISEASE MODIFYING TREATMENT OPTIONS approved for SSc¹

Management of the condition **FOCUSES ON RELIEF OF SYMPTOMS**, to **PREVENT DISEASE WORSENING** and **MINIMISE DISABILITY**¹



There is a **SIGNIFICANT NEED FOR AN EFFECTIVE THERAPY** that treats the underlying **CAUSES OF THE DISEASE**



References

- NHS Choices. Scleroderma. Available at: <http://www.nhs.uk/conditions/scleroderma/Pages/Introduction.aspx>. [Last accessed: 28 May 2015].
- Khanna D, et al. Evidence-based management of rapidly progressing systemic sclerosis. *Best Pract Res Clin Rheumatol*. 2010;24(3):387-400.
- Patient UK. Systemic Sclerosis. Available at: <http://www.patient.co.uk/doctor/systemic-sclerosis-scleroderma> [Last accessed: 8 May 2015].
- University of Michigan Health System, Scleroderma Program, Division of Rheumatology. What is Scleroderma? Available at: <http://www.med.umich.edu/scleroderma/patients/scleroderma.htm> [Last accessed: 1 May 2015].
- Arthritis Research UK. Systemic Sclerosis. Available at: http://www.arthritisresearchuk.org/~media/Files/Arthritis-information/Conditions/2036%20Systemic%20sclerosis_scleroderma%2014-1.aslx [Last accessed: 28 May 2015].
- Barnes J, et al. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy and environmental triggers. *Curr Opin Rheumatol*. 2012;24(2):165-170.
- Mayes MD, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. *Arthritis Rheum*. 2003;48:2246-2255.
- Benrud-Larson LM, et al. Body image dissatisfaction among women with scleroderma: extent and relationship to psychosocial function. *Health Psychol*. 2003;22(2):130-139.
- Suarez-Almazor ME, et al. Disease and symptom burden in systemic sclerosis: a patient perspective. *J Rheumatol*. 2007 Aug;34(8):1718-26.
- Roca RP, et al. Depressive symptoms associated with scleroderma. *Arthritis Rheum*. 1996;39(6):1035-1040.
- Thombs BD, et al. Depression in patients with systemic sclerosis: a systematic review of the evidence. *Arthritis Rheum*. 2007;57(6):1089-1097.